Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma
Jiaxin Xie, Yuwei Zhang, Qi Zhang, Yifang Han, Jianhua Yin, Rui Pu, Qiuxia Shen, Wei Lu, Yan Du, Jun Zhao, Xue Han, Hongwei Zhang, Guangwen Cao – 5 February 2013 – Hepatitis B virus (HBV) mutations and signal transducer and activator of transcription 3 (STAT3) activation are closely associated with hepatocellular carcinoma (HCC). However, single nucleotide polymorphisms (SNPs) of STAT3 have not been implicated in HCC susceptibility. This study was designed to evaluate the effect of STAT3 SNPs and their interactions with HBV mutations on HCC risk.
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
Stuart C. Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B. Martins, Leland J. Yee, John F. Flaherty, Kathryn M. Kitrinos, Vinod K. Rustgi, Patrick Marcellin – 30 January 2013 – We evaluated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA ≥9 log10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment.
Notch2 signaling and undifferentiated liver cancers: Evidence of hepatic stem/progenitor cell origin
Vincenzo Cardinale, Guido Carpino, Lola M. Reid, Eugenio Gaudio, Domenico Alvaro – 29 January 2013
Correction
Jason D. Coombes, Wing‐Kin Syn – 29 January 2013
Reply
Charalambos G. Antoniades, Julia Wendon – 28 January 2013
Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: Effect of patient and nonpatient factors
Jessica A. Davila, Jennifer R. Kramer, Zhigang Duan, Peter A. Richardson, Gia L. Tyson, Yvonne H. Sada, Fasiha Kanwal, Hashem B. El‐Serag – 28 January 2013 – The delivery of treatment for hepatocellular carcinoma (HCC) could be influenced by the place of HCC diagnosis (hospitalization versus outpatient), subspecialty referral following diagnosis, as well as physician and facility factors. We conducted a study to examine the effect of patient and nonpatient factors on the place of HCC diagnosis, referral, and treatment in Veterans Administration (VA) hospitals in the United States.
Predictors of poor outcome in patients w ith autoimmune hepatitis: A population‐based study
Jing Hieng Ngu, Richard Blair Gearry, Chris Miles Frampton, Catherine A.M. Stedman – 28 January 2013 – Autoimmune hepatitis (AIH) can lead to cirrhosis, hepatic failure, and death. We aimed to identify predictors of advanced liver fibrosis at presentation, predictors of incomplete response to initial immunosuppression, and predictors of poor liver‐related outcomes in the population‐based AIH cohort from Canterbury, New Zealand. Cases diagnosed after 1980 that fulfilled standard diagnostic criteria were included.
Reply
Monika Ferlitsch, Markus Peck‐Radosavljevic, Arnulf Ferlitsch – 28 January 2013
Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect
R. Scott Rector, E. Matthew Morris, Suzanne Ridenhour, Grace M. Meers, Fong‐Fu Hsu, John Turk, Jamal A. Ibdah – 28 January 2013 – Earlier reports suggest a link between mitochondrial dysfunction and development of hepatic insulin resistance. Here we used a murine model heterozygous (HET) for a mitochondrial trifunctional protein (MTP) gene defect to determine if a primary defect in mitochondrial long‐chain fatty acid oxidation disrupts hepatic insulin action.